Plasma exchange in inflammatory demyelinating disorders of the central nervous system: reasonable use in the clinical practice

Abstract

Plasma exchange (PLEX) is a therapeutic apheresis modality in which the plasma is separated from inflammatory factors such as circulating autoreactive immunoglobulins, the complement system, and cytokines, and its therapeutic effect is based on the removal of these mediators of pathological processes. Plasma exchange is well established for various neurological disorders, and it is applied successfully in central nervous system inflammatory demyelinating diseases (CNS-IDD). It mainly modulates the humoral immune system; thus, it has a greater theoretical effect in diseases with prominent humoral mechanisms, such as neuromyelitis optica (NMO). However, it also has a proven therapeutic effect in multiple sclerosis (MS) attacks. Several studies have suggested that patients with severe attacks of CNS-IDD have poor response to steroid therapy but show clinical improvement after the PLEX treatment. Currently, PLEX is generally established only as a rescue therapy for steroid unresponsive relapses. However, there are still research gaps in the literature regarding plasma volume, number of sessions, and how early the apheresis treatment needs to started. Thus, in the present article, we summarize the clinical studies and meta-analyses, especially about MS and NMO, outlining clinical data regarding the experience with therapeutic PLEX in severe attacks of CNS-IDD, the clinical improvement rates, the prognostic factors of a favorable response, and highlighting the likely role of the early apheresis treatment. Further, we have gathered this evidence and suggested a protocol for the treatment of CNS-IDD with PLEX in the routine clinical practice.

Resumo

Plasmaférese (PLEX) é um procedimento em que o plasma é separado de fatores inflamatórios como imunoglobulinas autorreativas circulantes, sistema complemento e citocinas, e seu efeito terapêutico se baseia na remoção desses mediadores de processos patológicos. A PLEX está bem estabelecida no tratamento de diversos distúrbios neurológicos, e é utilizada com sucesso em surtos de doenças desmielinizantes inflamatórias do sistema nervoso central (CNS-IDD). A PLEX modula principalmente o sistema imunológico humoral; assim, tem efeito teórico maior em doenças com mecanismos patológicos humorais proeminentes, como a neuromielite óptica (NMO). No entanto tem também efeito terapêutico comprovado em surtos de esclerose múltipla (EM). Estudos sugerem que a corticoterapia é pouco eficaz em pacientes com surtos graves de CNS-IDD, e que estes apresentam melhora clínica após o tratamento com PLEX. Atualmente, a PLEX está geralmente estabelecida apenas como terapia de resgate para surtos não responsivos a corticosteroides. No entanto, há lacunas na literatura sobre a quantidade de troca de volume plasmático, o número de sessões, e o tempo de início da aférese terapêutica. Dessa forma, resumimos neste artigo estudos clínicos e metanálises, especialmente sobre EM e NMO, e delineamos os dados clínicos sobre a experiência com o uso de PLEX em surtos graves de CNS-IDD, as taxas de melhora clínica, os fatores prognósticos para uma resposta favorável, e destacamos o provável papel do tratamento precoce nestes casos. Em um segundo momento, reunimos essas evidências em uma sugestão de protocolo de tratamento de CNS-IDD com PLEX na prática clínica rotineira.

Keywords

Plasma Exchange - Demyelinating Autoimmune Diseases, CNS - Central Nervous System Diseases - Neuromyelitis Optica - Multiple Sclerosis

Palavras-chave

Troca Plasmática - Doenças Autoimunes Desmielinizantes do Sistema Nervoso Central - Doenças do Sistema Nervoso Central - Neuromielite Óptica - Esclerose Múltipla

Authors' Contributions

ALGQ: conceptualization, data curation, investigation, methodology, validation, writing of the original draft, and writing: review & editing; HRSN: conceptualization, methodology, project administration, supervision, and writing: review & editing; TTK: conceptualization, methodology, writing of the original draft, and writing: review & editing; SMCAS: conceptualization, supervision, validation, visualization, and writing: review & editing.

Publication History

Received: 10 December 2021

Accepted: 09 May 2022

Article published online:
14 April 2023

• References

• 1 Brecher ME. Plasma exchange: why we do what we do. J Clin Apher 2002; 17 (04) 207-211 DOI: 10.1002/jca.10041.
• 2 Schröder A, Linker RA, Gold R. Plasmapheresis for neuroinflammatory disorders. Clin Exp Neuroimmunol 2010; 1 (03) 95-102 DOI: 10.1111/j.1759-1961.2010.00010.x.
• 3 Llufriu S, Castillo J, Blanco Y. et al. Plasma exchange for acute attacks of CNS demyelination: Predictors of improvement at 6 months. Neurology 2009; 73 (12) 949-953 DOI: 10.1212/WNL.0b013e3181b879be.
• 4 Bonnan M, Cabre P. Plasma exchange in severe attacks of neuromyelitis optica. Mult Scler Int 2012; 2012: 787630 DOI: 10.1155/2012/787630.
• 5 Bonnan M, Valentino R, Olindo S, Mehdaoui H, Smadja D, Cabre P. Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler 2009; 15 (04) 487-492 DOI: 10.1177/1352458508100837.
• 6 Magaña SM, Keegan BM, Weinshenker BG. et al. Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol 2011; 68 (07) 870-878 DOI: 10.1001/archneurol.2011.34.
• 7 Weinshenker BG. Plasma exchange for severe attacks of inflammatory demyelinating diseases of the central nervous system. J Clin Apher 2001; 16 (01) 39-42 DOI: 10.1002/jca.1010.
• 8 Lassmann H, Brück W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 2001; 7 (03) 115-121 DOI: 10.1016/S1471-4914(00)01909-2.
• 9 Berkovich R. Treatment of acute relapses in multiple sclerosis. Neurotherapeutics 2013; 10 (01) 97-105 DOI: 10.1007/s13311-012-0160-7.
• 10 Frohman EM, Shah A, Eggenberger E, Metz L, Zivadinov R, Stüve O. Corticosteroids for multiple sclerosis: I. Application for treating exacerbations. Neurotherapeutics 2007; 4 (04) 618-626 DOI: 10.1016/j.nurt.2007.07.008.
• 11 Rolfes L, Pfeuffer S, Ruck T, Melzer N, Pawlitzki M, Heming M, Brand M, Wiendl H, Meuth SG. Therapeutic Apheresis in Acute Relapsing Multiple Sclerosis: Current Evidence and Unmet Needs-A Systematic Review. J Clin Med 2019; Oct 4; 8 (10) 1623 DOI: 10.3390/jcm8101623.
• 12 Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A. Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2011; 76 (03) 294-300 DOI: 10.1212/WNL.0b013e318207b1f6.
• 13 Sellebjerg F, Barnes D, Filippini G. et al; EFNS Task Force on Treatment of Multiple Sclerosis Relapses. EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses. Eur J Neurol 2005; 12 (12) 939-946 DOI: 10.1111/j.1468-1331.2005.01352.x.
• 14 Marques VD, Passos GRD, Mendes MF. et al. Brazilian consensus for the treatment of multiple sclerosis: Brazilian academy of neurology and brazilian committee on treatment and research in multiple sclerosis. Arq Neuropsiquiatr 2018; 76 (08) 539-554 DOI: 10.1590/0004-282X20180078.
• 15 Weinshenker BG, O'Brien PC, Petterson TM. et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999; 46 (06) 878-886 DOI: 10.1002/1531-8249(199912)46:6<878:AID-ANA10>3.0.CO;2-Q.
• 16 Keegan M, Pineda AA, McClelland RL, Darby CH, Rodriguez M, Weinshenker BG. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 2002; 58 (01) 143-146 DOI: 10.1212/wnl.58.1.143.
• 17 Correia I, Ribeiro JJ, Isidoro L. et al. Plasma exchange in severe acute relapses of multiple sclerosis - Results from a Portuguese cohort. Mult Scler Relat Disord 2018; 19 (19) 148-152 DOI: 10.1016/j.msard.2017.12.001.
• 18 Trebst C, Reising A, Kielstein JT, Hafer C, Stangel M. Plasma exchange therapy in steroid-unresponsive relapses in patients with multiple sclerosis. Blood Purif 2009; 28 (02) 108-115 DOI: 10.1159/000224630.
• 19 Pfeuffer S, Rolfes L, Bormann E, Sauerland C, Ruck T, Schilling M, Melzer N, Brand M, Pul R, Kleinschnitz C, Wiendl H, Meuth SG. Comparing Plasma Exchange to Escalated Methyl Prednisolone in Refractory Multiple Sclerosis Relapses. J Clin Med 2019; Dec 22; 9 (01) 35 DOI: 10.3390/jcm9010035.
• 20 Ehler J, Koball S, Sauer M. et al. Therapeutic plasma exchange in glucocorticosteroid-unresponsive patients with Clinically Isolated Syndrome. Ther Apher Dial 2014; 18 (05) 489-496 DOI: 10.1111/1744-9987.12176.
• 21 Habek M, Barun B, Puretić Z, Brinar VV. Treatment of steroid unresponsive relapse with plasma exchange in aggressive multiple sclerosis. Ther Apher Dial 2010; 14 (03) 298-302 DOI: 10.1111/j.1744-9987.2009.00794.x.
• 22 Blechinger S, Ehler J, Bsteh G. et al. Therapeutic plasma exchange in steroid-refractory multiple sclerosis relapses. A retrospective two-center study. Ther Adv Neurol Disord 2021; 14: 1756286420975642 DOI: 10.1177/1756286420975642.
• 23 Keegan M, König F, McClelland R. et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 2005; 366 (9485): 579-582 DOI: 10.1016/S0140-6736(05)67102-4.
• 24 Stork L, Ellenberger D, Beißbarth T. et al. Differences in the reponses to apheresis therapy of patients with 3 histopathologically classified immunopathological patterns of multiple sclerosis. JAMA Neurol 2018; 75 (04) 428-435 DOI: 10.1001/jamaneurol.2017.4842.
• 25 Lucchinetti CF, Mandler RN, McGavern D. et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002; 125 (Pt 7): 1450-1461 DOI: 10.1093/brain/awf151.
• 26 Lennon VA, Wingerchuk DM, Kryzer TJ. et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364 (9451): 2106-2112 DOI: 10.1016/S0140-6736(04)17551-X.
• 27 Kim SH, Kim W, Huh SY, Lee KY, Jung IJ, Kim HJ. Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-aquaporin-4 antibody levels. J Clin Neurol 2013; 9 (01) 36-42 DOI: 10.3988/jcn.2013.9.1.36.
• 28 Trebst C, Jarius S, Berthele A. et al; Neuromyelitis Optica Study Group (NEMOS). Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 2014; 261 (01) 1-16 DOI: 10.1007/s00415-013-7169-7.
• 29 Kleiter I, Gahlen A, Borisow N. et al; Neuromyelitis Optica Study Group. Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol 2016; 79 (02) 206-216 DOI: 10.1002/ana.24554.
• 30 Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999; 53 (05) 1107-1114 DOI: 10.1212/wnl.53.5.1107.
• 31 Yu HH, Qin C, Zhang SQ. et al. Efficacy of plasma exchange in acute attacks of neuromyelitis optica spectrum disorders: A systematic review and meta-analysis. J Neuroimmunol 2020; 350 (August 2020): 577449 DOI: 10.1016/j.jneuroim.2020.577449.
• 32 Padmanabhan A, Connelly-Smith L, Aqui N. et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher 2019; 34 (03) 171-354 DOI: 10.1002/jca.21705.
• 33 Jiao Y, Cui L, Zhang W. et al. Plasma Exchange for Neuromyelitis Optica Spectrum Disorders in Chinese Patients and Factors Predictive of Short-term Outcome. Clin Ther 2018; 40 (04) 603-612 DOI: 10.1016/j.clinthera.2018.03.007.
• 34 Watanabe S, Nakashima I, Misu T. et al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 2007; 13 (01) 128-132 DOI: 10.1177/1352458506071174.
• 35 Abboud H, Petrak A, Mealy M, Sasidharan S, Siddique L, Levy M. Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange. Mult Scler 2016; 22 (02) 185-192 DOI: 10.1177/1352458515581438.
• 36 Kumawat BL, Choudhary R, Sharma CM, Jain D, Hiremath A. Plasma exchange as a first line therapy in acute attacks of neuromyelitis optica spectrum disorders. Ann Indian Acad Neurol 2019; 22 (04) 389-394 DOI: 10.4103/aian.AIAN_365_19.
• 37 Kumar R, Paul BS, Singh G, Kaur A. Therapeutic efficacy of plasma exchange in neuromyelitis optica. Ann Indian Acad Neurol 2018; 21 (02) 140-143 DOI: 10.4103/aian.AIAN_330_17.
• 38 Palacios-Mendoza MA, Martínez Ginés ML, Melgarejo Otálora PJ. et al. Plasma exchange in acute attacks of demyelinating diseases of the central nervous system: clinical outcomes and predictors of response. Neurol Sci 2020; 41 (09) 2569-2574 DOI: 10.1007/s10072-020-04382-w.
• 39 Aungsumart S, Apiwattanakul M. Clinical outcomes and predictive factors related to good outcomes in plasma exchange in severe attack of NMOSD and long extensive transverse myelitis: Case series and review of the literature. Mult Scler Relat Disord 2017; 13 (13) 93-97 DOI: 10.1016/j.msard.2017.02.015.
• 40 Bonnan M, Valentino R, Debeugny S. et al. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry 2018; 89 (04) 346-351 DOI: 10.1136/jnnp-2017-316286.
• 41 Kosiyakul P, Songwisit S, Ungprasert P, Siritho S, Prayoonwiwat N, Jitprapaikulsan J. Effect of plasma exchange in neuromyelitis optica spectrum disorder: A systematic review and meta-analysis. Ann Clin Transl Neurol 2020; 7 (11) 2094-2102 DOI: 10.1002/acn3.51203.
• 42 Srisupa-Olan T, Siritho S, Kittisares K, Jitprapaikulsan J, Sathukitchai C, Prayoonwiwat N. Beneficial effect of plasma exchange in acute attack of neuromyelitis optica spectrum disorders. Mult Scler Relat Disord 2018; 20 (20) 115-121 DOI: 10.1016/j.msard.2018.01.010.
• 43 Ito S. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology 2009; 73 (19) 1604 , author reply 1604–1605 DOI: 10.1212/WNL.0b013e3181bd6a85.
• 44 Huang X, Wu J, Xiao Y, Zhang Y. Timing of plasma exchange for neuromyelitis optica spectrum disorders: A meta-analysis. Mult Scler Relat Disord 2021; 48: 102709 DOI: 10.1016/j.msard.2020.102709.
• 45 Brunot S, Vukusic S, Fromont A. et al. Échanges plasmatiques dans les maladies inflammatoires démyélinisantes aiguës sévères du système nerveux central. Presse Med 2011; 40 (05) e271-e278 DOI: 10.1016/j.lpm.2010.11.022.
• 46 Songthammawat T, Srisupa-Olan T, Siritho S. et al. A pilot study comparing treatments for severe attacks of neuromyelitis optica spectrum disorders: Intravenous methylprednisolone (IVMP) with add-on plasma exchange (PLEX) versus simultaneous ivmp and PLEX. Mult Scler Relat Disord 2020; 38 (October 2019): 101506 DOI: 10.1016/j.msard.2019.101506.
• 47 Kleiter I, Gahlen A, Borisow N. et al; NEMOS (Neuromyelitis Optica Study Group). Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions. Neurol Neuroimmunol Neuroinflamm 2018; 5 (06) e504 DOI: 10.1212/NXI.0000000000000504.
• 48 Bennetto L, Totham A, Healy P, Massey E, Scolding N. Plasma exchange in episodes of severe inflammatory demyelination of the central nervous system. A report of six cases. J Neurol 2004; 251 (12) 1515-1521 DOI: 10.1007/s00415-004-0588-8.
• 49 Ong ZM, Schee JP, Viswanathan S. Therapeutic Plasma Exchange in Neuromyelitis Optica Spectrum Disorders and Related Disorders in Resource-Limited Settings: Outcomes in a Multiethnic Single-Center Population. Ther Apher Dial 2020; 24 (03) 312-323 DOI: 10.1111/1744-9987.13446.
• 50 Kaplan AA. Therapeutic plasma exchange: a technical and operational review. J Clin Apher 2013; 28 (01) 3-10 DOI: 10.1002/jca.21257.
• 51 Holroyd KB, Manzano GS, Levy M. Update on neuromyelitis optica spectrum disorder. Curr Opin Ophthalmol 2020; 31 (06) 462-468 DOI: 10.1097/ICU.0000000000000703.
• 52 Olek MJ, Howard J. Treatment of acute exacerbations of multiple sclerosis in adults. Post TW. ed. UpToDate. Waltham, MA: UpToDate Inc.; http://www.uptodate.com . Accessed April 06, 2022